FDA approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.
FDA authorized Memorial Sloan Kettering Cancer Center's Integrated Mutation Profiling of Actionable Cancer Targets tumor profiling test, an in vitro diagnostic test that can identify a higher number of genetic mutations that may be found in various cancers than any test previously reviewed by the agency.
Albert de la Chapelle, professor in the department of cancer biology and genetics at Ohio State University, has received a lifetime achievement award from the Collaborative Group of the Americas on Inherited Colorectal Cancer, which was established to improve understanding of inherited colorectal cancer and the clinical management of affected families, particularly those living in the Americas.
Neil Gallagher joined AbbVie in a newly created role of vice president & head, Global Oncology Development.
Ramin Shiekhattar, a Sylvester Comprehensive Cancer Center genetics researcher, has received a “Pioneer Award” and a five-year $5+ million grant from the NIH.
Anita Mattson, associate professor of chemistry and biochemistry at Worcester Polytechnic Institute, received a $1.7-million award from NIH to develop a new class of catalysts that could make it possible to reliably synthesize organic compounds that hold the promise of treating cancers that have become resistant to commonly used chemotherapy. The catalysts may also open the door to a new approach to discovering drugs for cancer and other diseases.
LUNGevity Foundation announced a parternship with the ALK Positive patient group to support the new ALK-Positive Lung Cancer Transformational Research Award Program.
Michael Caligiuri, who over the past 14 years demonstrated virtuosity in recruitment, lobbying, and fundraising, building the third-largest cancer hospital in the U.S., has stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
In 2010, John Knox Singleton, the CEO of the Inova Health System, had several meetings with John Niederhuber, a surgeon and scientist who had just been replaced as NCI director.
HALOZYME THERAPEUTICS INC. said FDA has accepted Genentech’s Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications. This is a co-formulation with Halozyme’s proprietary recombinant human hyaluronidase enzyme (ENHANZE platform), approved and marketed under the MabThera SC brand in countries outside the U.S. Halozyme Therapeutics is a biotechnology company focused... […]
